Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
The study, published March 20, 2013, on the website of The American Journal of Psychiatry, shows that infants born to mothers who took SSRIs had similar weights, lengths, and head circumferences over the course of their first year as infants born to women who did not take SSRIs.
For the study, pregnant women were evaluated at weeks 20, 30, and 36 of gestation, and mother-and-infant pairs were assessed at 2, 12, 26, and 52 weeks postpartum. Three nonoverlapping groups of women were defined according to their pregnancy exposures: 1) no SSRI and no depression (N=97), 2) SSRI (N=46), and 3) major depression without SSRI (N=31). Maternal demographic and clinical characteristics and newborn outcomes were compared among exposure groups. Infant weight, length, and head circumference were measured by a physician or physician assistant who was blind to depression and SSRI exposure status at each postpartum time point.
The researchers found that neither antenatal major depression nor SSRI exposure was significantly associated with infant weight, length, or head circumference. In addition, the researchers noted, the interaction of group and prepregnancy body mass index was evaluated, and no significant synergistic effect was identified.
Late third-trimester ultrasound accurately predicts large for gestational age births
February 17th 2025A new study confirms that estimating fetal weight with ultrasound between 35 to 38 weeks’ gestation strongly predicts large for gestational age births, helping guide clinical management decisions.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Removing parental consent reduces delays in adolescent abortion care
February 12th 2025A new study links the removal of parental consent requirements for abortion in Massachusetts to significantly earlier gestational age at the time of the procedure, highlighting the impact of reduced barriers on timely reproductive care.
Read More